Free tool
FAERS Monitor: Durezol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022212 or its brand name (Durezol, Difluprednate). Reports on generic versions are filed under their own applications.
Reports
3,862
Serious
1,778
46% of reports
Hospitalization
649
Death reported
126
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
Nothing to show.
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 6 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 9 |
| 2011 | 29 |
| 2012 | 52 |
| 2013 | 68 |
| 2014 | 80 |
| 2015 | 169 |
| 2016 | 533 |
| 2017 | 578 |
| 2018 | 355 |
| 2019 | 402 |
| 2020 | 338 |
| 2021 | 243 |
| 2022 | 236 |
| 2023 | 256 |
| 2024 | 191 |
| 2025 | 177 |
| 2026 | 124 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,297 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.